Cannabis News

Category: News

Current cannabis news and information. Mary Jane’s Post is marijuana, hemp, and CBD news publication. Find cannabis news from around the world.

  • What A “Full Panel” Cannabis Lab Test Really Includes, State by State

    If you buy or sell legal cannabis, you see the phrase “full panel tested” everywhere. It sounds reassuring, but what does it actually cover?

    Here is the key point: “full panel” is a marketing phrase, not a legal one. The real cannabis lab testing requirements are written into each state’s rules, and they do not all match.

    This guide breaks down what a “full panel” usually means, how states differ, what has changed by 2025, and how to confirm your lab is using the right panel for your market.

    Important disclaimer about regulations

    Cannabis rules shift often and sometimes with little notice. Emergency rules, guidance memos, and new contaminants show up every year.

    This article is for information only and is not legal or regulatory advice. Always confirm current rules with your state cannabis authority or other official sources before making decisions.

    For a high‑level overview of where cannabis is legal, you can start with this map of marijuana legality by state in 2025, then drill into testing rules for your specific market.

    What “full panel” usually means on a cannabis COA

    Cannabis being prepared for analysis in a lab
    Detailed view of cannabis being prepared in a lab for analysis. Photo by Jess Loiterton

    When a lab or brand says “full panel,” they usually mean a package of safety and potency tests sold together. The catch is that two labs can use that phrase and run different analytes.

    A typical “full panel” bundle for inhalable flower or vapes often includes:

    • Potency (THC, CBD, and other cannabinoids)
    • Terpenes (optional in many states, but common in the panel)
    • Residual solvents (for concentrates and vapes)
    • Pesticides
    • Heavy metals
    • Microbial contaminants (bacteria, yeast, mold, often Aspergillus species)
    • Mycotoxins (toxins from mold, like aflatoxins)
    • Moisture content and water activity
    • Sometimes foreign material or filth

    State rules may only require some of these for a given product type. A lab can still market the bundle as “full panel” as long as it also covers the state’s minimum.

    So the important question is not “Is it full panel,” but “Does this panel match my state’s current regulatory requirements for this product type?”

    Core cannabis lab testing requirements most states share

    Infographic of a cannabis full panel lab report with sections for safety tests
    Infographic-style illustration of a cannabis “full panel” lab report, including potency and safety sections. Image created with AI.

    By 2025, most legal markets include the same basic safety pillars, even if the exact limits differ.

    Potency:
    States require accurate THC and CBD results, usually within 10 to 15 percent of the labeled value. Some also require totals for minor cannabinoids or “total THC” for hemp.

    Pesticides:
    Labs screen for dozens of agricultural chemicals at very low levels. Some states use long, strict lists, while others use shorter target lists. Limits and target compounds vary widely.

    Heavy metals:
    Most programs require testing for at least lead, arsenic, cadmium, and mercury. Limits are usually based on daily exposure from the product type, for example inhaled vs edible.

    Microbes and pathogens:
    Typical targets include total yeast and mold, bacteria like E. coli and Salmonella, and, in many states now, pathogenic Aspergillus species. For a deeper look at how states differ, see this overview of cannabis microbial testing regulations by state.

    Mycotoxins:
    Tests commonly include aflatoxins and ochratoxin A. These have low action limits because they can be dangerous even at small doses.

    Water activity and moisture:
    Water activity (aw) predicts how easily mold will grow. Many states cap aw for flower and require either water activity or a combination of aw and moisture content.

    These are the testing “bones.” States then add their own twists on top.

    How states differ: California, Colorado, New York, Michigan, Florida

    Infographic U.S. map highlighting cannabis lab testing differences between key states
    Infographic-style U.S. map highlighting key cannabis states and core lab test categories. Image created with AI.

    To see how “full panel” can shift, compare a few major markets as of late 2025. This table is simplified, but it shows the flavor of the differences.

    StatePesticide approachMicrobial focus (incl. Aspergillus)Heavy metalsMycotoxins & water activityExtra notes for operators
    CaliforniaLong, strict list, low action limitsTargets six pathogens, including four Aspergillus sppRequiredBoth required for many productsOften seen as one of the strictest safety programs
    ColoradoBroad panel, evolving with guidanceIncludes Aspergillus and general microbial countsRequiredCommonly requiredEarly adopter state, rules still refine over time
    New YorkDetailed pesticide rules by product categoryPathogens plus total counts for various product typesRequiredRequired, tied to product typeStrong focus on sampling procedures and ISO accreditation
    MichiganPesticides panel similar to other mature statesIncludes Aspergillus species testingRequiredRequiredActive auditing of labs and ongoing rule updates
    FloridaPesticides with medical patient focusMolds and broader microbiological screeningRequiredWater activity plus moisture in many casesMedical-only market shapes strict patient safety focus

    On top of that, some states issue detailed testing manuals or memos that add color to the rules. New Jersey, for example, publishes updated guidance like the NJ-CRC testing guidance, which lays out sampling rules and the current panel.

    Trends by 2025 include:

    • More states requiring Aspergillus-specific testing, especially for inhalable products
    • Wider use of mandatory mycotoxin testing, not just for high-risk forms
    • Regular tightening of detection limits for pesticides and residual solvents
    • Clearer water activity thresholds for flower and some edibles

    Two neighboring states might both say “full panel,” yet require different analyte lists, limits, and product categories. That is why local knowledge matters.

    Where to find your state’s official cannabis lab testing requirements

    The safest path is to work from primary or trusted secondary sources, then map that to your lab’s panel.

    Helpful resources include:

    Use these as a map, then always click through to the current state rules or official FAQs before you change a SOP or label.

    Best practices to confirm your lab is on the right panel

    Even in a single state, labs may design different “full panel” bundles. Here are practical steps to stay aligned.

    Ask for the regulatory panel in writing.
    Request a document or link that shows exactly which state rules or guidance your lab’s panel is built to satisfy, broken out by product type.

    Compare the CoA to the rule text.
    Pull a recent Certificate of Analysis and line it up with your state’s contaminant list. Check that required analytes like Aspergillus or mycotoxins actually appear on the report.

    Verify accreditation and licensing.
    Make sure the lab is licensed in your state and ISO/IEC 17025 accredited where required. Regulators often expect this as a baseline.

    Schedule regular rule checks.
    Assign someone in compliance to review cannabis lab testing requirements at least quarterly, or whenever the state issues emergency rules. Keep a change log and update SOPs.

    Train buyers and sales staff.
    Dispensary buyers and sales teams should understand, in plain terms, what a compliant “full panel” looks like for your market so they can spot red flags on incoming COAs.

    Closing thoughts on “full panel” cannabis testing

    “Full panel” sounds simple, but under the hood it is a moving target shaped by each state’s rules. As mycotoxins, Aspergillus testing, and water activity limits spread across the map, that target keeps shifting.

    If you treat the phrase as a starting point and always trace it back to your own state’s written rules, you turn a vague label into a clear standard. In a fast-changing market, that clarity around cannabis lab testing requirements is one of the most valuable forms of risk control you can build into your operation.

  • What Federal Cannabis Rescheduling To Schedule III Would Change For Patients And Businesses

    What would it actually mean if the federal government moved cannabis to Schedule III instead of Schedule I?

    Headlines make it sound huge. For patients, business owners, and investors, the real story is more mixed: big changes in some areas, very little in others.

    This guide breaks down how federal cannabis rescheduling to Schedule III would work, what it could change in daily life, and where big questions still remain.

    Quick primer: how drug schedules work under federal law

    Under the federal Controlled Substances Act, drugs are grouped into five “schedules” based on medical use and risk of abuse.

    • Schedule I drugs are defined as having no accepted medical use and a high potential for abuse. Heroin and LSD are in this category. Marijuana is still in Schedule I as of December 2025. Doctors cannot legally prescribe Schedule I drugs, and research requires heavy approvals.
    • Schedule III drugs have accepted medical uses and a lower risk of abuse than Schedules I or II. Examples include ketamine and some anabolic steroids. Doctors can prescribe Schedule III drugs, pharmacies can dispense them, and companies can manufacture them if they follow DEA rules.

    Moving cannabis from Schedule I to Schedule III would not make it “uncontrolled.” It would still be a regulated drug, but in a category that the federal government treats as having medical value.

    Where federal cannabis rescheduling stands right now

    As of late 2025, rescheduling is proposed but not final.

    In 2023, federal health officials recommended moving marijuana to Schedule III. The Drug Enforcement Administration (DEA) followed with a proposed rule in 2024 and began a formal review. Hearings and legal challenges have slowed the process, and no final rule has taken effect yet.

    If you want a detailed timeline and FAQ, the Marijuana Policy Project’s Q&A on DEA rescheduling is a good reference.

    Any final rule could still change details, so everything below describes what is likely, not guaranteed.

    How Schedule III could affect medical cannabis patients

    For patients, the most important shift is recognition. Schedule III status would mean the federal government finally accepts that cannabis has medical use.

    That recognition can ripple through the system. Doctors who have been cautious may feel more comfortable talking about cannabis as a treatment option. Medical schools and hospitals may be more willing to study it or include it in pain and palliative care discussions.

    However, rescheduling would not instantly turn dispensary products into standard prescription drugs. To be prescribed like other Schedule III medications, individual cannabis products would still need to go through the Food and Drug Administration (FDA) drug approval process. That process usually takes years and requires large, controlled studies.

    So in the near term:

    • Patients would likely still get cannabis from state-licensed dispensaries using medical cards, not from regular pharmacies.
    • Doctors in many states would keep “recommending” cannabis under state law, even though federal law now recognizes medical use in general.

    Where patients may see faster change is in research and clinical guidance. With Schedule III status, universities and hospitals face fewer federal hurdles to run studies. More robust science could lead to better dosing guidelines, clearer risk profiles, and new formulations. The PBS NewsHour overview of marijuana reclassification highlights how researchers expect their work to get easier if Schedule III moves forward.

    Rescheduling might also help in some real-life conflict areas. Judges, employers, and housing providers sometimes treat medical cannabis more harshly than other medicines because it is Schedule I. Schedule III status will not force them to change policies, but it gives patients a stronger argument that their treatment is legitimate.

    For a patient-focused perspective, you can also look at this explanation from The Healing Clinics of potential medical changes.

    What Schedule III could mean for cannabis businesses

    For state-licensed cannabis businesses, Schedule III is mostly about money, risk, and long-term structure of the market.

    Relief from Section 280E and federal income taxes

    The single biggest financial change would be the end of Section 280E for cannabis.

    Section 280E is a part of the federal tax code that says businesses selling Schedule I or II drugs cannot deduct normal business expenses. That means many cannabis companies pay tax on gross income instead of profit. Effective tax rates can shoot above 60 percent.

    If cannabis moves to Schedule III, Section 280E would no longer apply to cannabis businesses. Dispensaries, cultivators, and manufacturers could deduct rent, payroll, marketing, and other ordinary costs like any other business.

    That shift could:

    • Reduce federal tax bills.
    • Help legal operators compete with illicit markets.
    • Make it easier for smaller operators to stay open.

    One open question is timing. It is not yet clear how the IRS would handle prior years or partial years if rescheduling takes effect mid-tax year. Businesses will want to work with tax advisors once final rules appear.

    Banking, payments, and access to capital

    Today, many cannabis businesses struggle to get basic banking. Some rely on cash because banks worry about federal money-laundering laws.

    Rescheduling to Schedule III would not rewrite banking statutes by itself, but it would lower the perceived legal risk of serving cannabis clients. More regional banks and credit unions may feel comfortable offering accounts, loans, and merchant services. Payment processors and insurers may also become more open to cannabis clients.

    Large national banks may still wait for clearer federal law or new banking-focused legislation. So improvement is likely to be gradual rather than overnight.

    Licenses, FDA rules, and interstate commerce

    Schedule III would bring cannabis into the standard framework for controlled medicines. That means:

    • Companies that want to sell FDA-approved cannabis drugs would need DEA registrations.
    • Manufacturing, distribution, and dispensing in that channel would follow strict tracking and security rules.

    At the same time, existing state-licensed adult-use and medical dispensaries would still operate under state law. How those systems interact with any future FDA-approved cannabis medicines is a major unanswered question.

    Rescheduling also does not create free interstate commerce for current state-market products. Shipping cannabis across state lines remains risky under federal law, especially when products are not part of a DEA/FDA controlled-drug system. States that ban cannabis can still block shipments into their borders.

    For a legal deep dive aimed at companies, the article “Schedule III Marijuana Would Still Be Regulated Marijuana” by Hyman, Phelps & McNamara explains how tight those controls can remain.

    What rescheduling would not change

    It is just as important to understand what Schedule III would not do.

    • No automatic federal legalization of adult use. Recreational cannabis would remain illegal under federal law, even if penalties and enforcement priorities shift.
    • No guaranteed expungement of past records. Rescheduling does not erase prior federal or state cannabis convictions. Those changes require separate laws or clemency programs.
    • No override of strict state laws. States that ban cannabis can keep those bans. Federal rescheduling does not force any state to allow dispensaries or medical programs.
    • No instant green light for every product. Some hemp-derived products and high-THC items already sit in gray areas. Schedule III might change how agencies view them, but it does not instantly approve or ban specific brands.

    If you want a myth-busting checklist, NORML’s breakdown of cannabis rescheduling myths versus reality is a useful companion read.

    Conclusion: planning for a Schedule III future

    Federal cannabis rescheduling to Schedule III would be a major shift in how the government talks about cannabis, treats patients, and taxes businesses. It would open doors for research and likely ease financial pressure on licensed operators, but it would stop short of full federal legalization.

    Because the rule is not final yet, smart planning means following updates from trusted sources, talking with qualified tax and legal advisors, and stress-testing your business or care decisions under different timelines.

    For patients, the key may be more honest conversations with providers and better research. For businesses, the key may be preparing for a more regulated but more stable federal environment.

    The details will matter, so the time to start paying close attention is now.

  • Will The Supreme Court End Federal Marijuana Prohibition? Inside Canna Provisions Inc. v. Garland

    On December 15, 2025, the United States Supreme Court is set to decide one simple but huge question: will it hear Canna Provisions Inc. v. Garland, a case that asks the Court to rethink federal marijuana prohibition as it applies to state-legal businesses?

    Right now, cannabis is legal in many states but still illegal under federal law. That split affects everything from banking and taxes to hiring, travel, and criminal risk. For cannabis business owners, workers, and patients, this gap is not a theory. It shows up in blocked loans, higher tax bills, and constant uncertainty.

    Readers of MaryJanes Post include people who run dispensaries, grow rooms, labs, and wellness clinics, as well as patients who just want safe, stable access. This guide walks through what the Canna Provisions case is about, what might happen after December 15, and how to prepare for different outcomes without panic or hype.

    What Is Federal Marijuana Prohibition and Why Does It Still Matter?

    Even with legal dispensaries on busy streets, federal law still treats marijuana like heroin. That clash shapes almost every part of the modern cannabis industry.

    Quick refresher on the Controlled Substances Act and Schedule I

    The Controlled Substances Act (CSA) is the main federal drug law. It sorts drugs into five “schedules” based on two things: medical use and potential for abuse.

    Schedule I is the tightest category. Under federal rules, a Schedule I drug:

    • Has a high risk of abuse
    • Has no accepted medical use in the eyes of federal law
    • Cannot be prescribed in normal medical practice

    Marijuana sits in Schedule I with drugs like heroin and LSD. This is true even though many states now have medical and adult-use programs, and even though federal health agencies have released research that points to medical benefits.

    For a clear legal background on how marijuana is treated under federal law, the article on Canna Provisions v. Garland gives a helpful snapshot of how the CSA is being challenged.

    How federal prohibition clashes with legal state cannabis markets

    Here is the basic conflict. States like Massachusetts, Illinois, Colorado, and many others license growers, manufacturers, and retailers. These businesses follow strict rules: seed-to-sale tracking, lab testing, child-resistant packaging, labelling, taxes, and inspections.

    Under the CSA, all of those same activities are still federal crimes. Growing one plant, running a multi-state dispensary chain, or transporting product between two licensed facilities are all illegal in the eyes of federal law.

    So you can have:

    • A city that welcomes dispensaries,
    • A state that regulates them like alcohol, and
    • A federal law that treats those same activities as drug trafficking.

    This split confuses law enforcement, regulators, landlords, and customers. It also creates messy questions, like what happens when someone passes a TSA checkpoint with legal state products or applies for a federal job after working in cannabis.

    Everyday problems federal prohibition creates for cannabis businesses

    Federal prohibition is not just about the risk of a raid. It shapes basic business tasks that other industries take for granted.

    Common pain points include:

    • Banking and payments: Many banks are still wary of cannabis, since handling marijuana money can be seen as money laundering under federal law. Some operators rely on cash, ATM workarounds, or small local banks. That raises security risks and makes bookkeeping harder.
    • Section 280E taxes: IRS Code Section 280E disallows standard business deductions for companies that “traffic” in Schedule I or II substances. For cannabis, that means normal costs like rent, marketing, and payroll may not be deducted. Tax bills can reach 60 to 80 percent of profit.
    • Insurance limits: Some large insurers avoid cannabis risks. Policies that do exist may cost more or cover less. That affects everything from product liability to property damage.
    • No legal transport across state lines: A licensed grower in Oregon cannot legally ship flower to a licensed shop in New York, even if both states want that trade. Every move across a state border is federal trafficking.
    • Public markets and investment: Many U.S. stock exchanges shy away from “plant-touching” cannabis companies that violate federal law. This pushes some listings to Canadian exchanges and keeps capital markets fragmented.
    • Constant background risk: Even if actual raids are rare in mature legal states, the threat is always there. A change in federal policy could shift enforcement priorities quickly.

    For medical patients, these issues show up as higher prices, fewer product options, and fear about what might happen when they travel or change jobs.

    Inside Canna Provisions Inc. v. Garland: The Case That Could Change Everything

    Canna Provisions Inc. v. Garland is a lawsuit brought by state-licensed cannabis businesses that operate legally in Massachusetts. They sued U.S. Attorney General Merrick Garland, arguing that the CSA reaches too far when it blocks or burdens activity that stays inside a legal state market.

    The case has drawn attention because it asks the courts to re-examine how far federal power goes in the current era of widespread state legalization. A detailed case summary and timeline are available in the public docket at Canna Provisions, Inc. v. Garland on CourtListener.

    Right now, the Supreme Court is not yet deciding who “wins”. The first step is simpler: will it hear the case at all?

    Who is suing and what are they asking the Supreme Court to do?

    Four Massachusetts cannabis companies, including Canna Provisions Inc., filed the original suit in 2023. They operate cultivation and retail businesses that follow state rules and sell only within Massachusetts.

    Their basic request is straightforward:

    • They want the Court to say that the federal government cannot use the CSA to punish or block cannabis activities that stay inside one state, as long as those activities are legal and regulated under that state’s law.

    In other words, if all of the growing, processing, and selling happens inside a legal state market, they argue that it should be outside the reach of federal marijuana prohibition.

    For a readable breakdown of the complaint and the lower-court decisions, the law firm Peters Brovner has a helpful overview in its write-up on Canna Provisions, Inc. et al. v. Garland.

    The core legal argument: states’ rights and the Commerce Clause

    The case rests on two key ideas from the U.S. Constitution:

    1. The Commerce Clause
      Congress can regulate “interstate commerce”, which means trade between states. In a 2005 case called Gonzales v. Raich, the Supreme Court said Congress could still ban marijuana under the CSA, even when it was grown at home in a legal state.

      The Canna Provisions plaintiffs say that situation has changed. They argue that when cannabis is grown, processed, and sold only inside one tightly regulated state market, it is not interstate commerce. So Congress should not be able to ban it under the Commerce Clause.

    2. States’ rights to regulate local markets
      States like Massachusetts have chosen to move marijuana out of the underground market and into licensed, taxed systems. The plaintiffs argue that the federal ban undercuts these state choices and harms lawful businesses and workers.

    Put more simply, the question they want the Court to answer is: how much control should Washington keep over purely in-state cannabis activity when a state has chosen to legalize and regulate it?

    Why this case is historic for federal marijuana law

    The Supreme Court has not fully addressed federal marijuana prohibition in the modern era of broad state legalization. Raich involved homegrown medical cannabis in California in the early 2000s, long before today’s multi-billion-dollar regulated markets.

    Since then, individual justices have written opinions that hint at concern about the conflict between state and federal law, but no recent case has forced the Court to squarely address the issue.

    Canna Provisions could be the first case that directly asks:

    • Does the CSA still apply the same way when more than half the states have legal markets?
    • Can Congress treat in-state, licensed cannabis like interstate drug trafficking?

    Investors, operators, and advocates see this as a possible turning point, even if the final result remains very uncertain.

    Key dates: what happens on December 15, 2025 and beyond

    Here is the short timeline to watch:

    • December 15, 2025: The Supreme Court is expected to announce whether it will grant “certiorari” in Canna Provisions Inc. v. Garland. Granting cert means the Court will hear the case. Denying cert means the lower-court ruling stands and the case ends.
    • If the Court says yes:
      • Written briefs from both sides and supporting groups would likely be filed through early and mid-2026.
      • Oral argument could happen in the spring of 2026.
      • A final decision would likely arrive by June or July 2026.
    • If the Court says no:
      • The First Circuit’s decision against Canna Provisions remains in place.
      • Federal marijuana prohibition continues as it is, unless Congress or federal agencies change it.

    So December 15 is not decision day on marijuana legalization. It is decision day on whether the Supreme Court is willing to take the question at all.

    What Could Happen Next: Possible Supreme Court Outcomes and Their Impact

    It helps to think about three main paths and what each could mean for businesses and patients.

    If the Supreme Court refuses the case: what a denial means for cannabis

    If the Court denies cert, the legal picture stays the same.

    • Marijuana remains Schedule I under the CSA.
    • Section 280E continues to apply to plant-touching businesses.
    • Banks and major payment processors keep weighing the same risks.
    • State-legal programs keep running, but always under the shadow of federal law.

    In that world, meaningful change would still need to come from:

    • Congress, through bills that reschedule or deschedule cannabis, address banking, and fix 280E.
    • Federal agencies, like the DEA and FDA, which can adjust scheduling and set medical or product rules.

    Advocates might bring other lawsuits in other circuits, but those would take years and might face the same roadblocks that Canna Provisions has already seen.

    If the Court hears the case but sides with federal prohibition

    The second path is that the Court grants cert, hears the case, and then rules that Congress can still ban marijuana, even in tightly regulated state markets.

    This would not change daily operations right away, but it would send a clear message:

    • The CSA still fully applies to state-legal marijuana.
    • The Commerce Clause gives Congress broad power in this area.

    That kind of ruling could:

    • Cool some investment and expansion plans.
    • Make banks and public markets even more cautious.
    • Push the focus back to Congress as the only real path for change.

    State markets would still run. Many governors and attorneys general support their own programs. But people who hoped for fast relief from 280E or banking problems through the courts would have to reset expectations.

    If the Court limits federal power over state legal cannabis

    The third path is the most dramatic. Here, the Court would say that the federal government cannot use the CSA to punish or block cannabis activities that stay inside a legal state’s borders.

    Even in that scenario, a few key points matter:

    • It would not create full national legalization.
    • It would not automatically allow interstate cannabis commerce.
    • It would not instantly rewrite the tax code or remove 280E.

    What might change:

    • State-legal operators would face much less fear of federal raids.
    • Banks could feel safer serving cannabis businesses that stay fully in-state.
    • Investors might gain confidence that state markets have long-term stability.
    • State regulators could treat cannabis more like alcohol, without worrying about direct conflict with the CSA.

    Congress would still need to tackle big questions, like:

    • Rescheduling or descheduling marijuana.
    • Setting national safety, labeling, and advertising rules.
    • Allowing and regulating interstate trade.
    • Fixing 280E for cannabis businesses.

    So this type of ruling would be a large step, not the final word.

    What this case does not do: interstate trade, hemp products, and rescheduling

    There is a lot of confusion around what Canna Provisions could cover. It helps to clear up some limits.

    This case does not directly:

    • Legalize moving marijuana across state lines. Even a pro-plaintiff ruling is likely to focus on in-state markets. Interstate trade would still need new laws or future cases.
    • Set rules for hemp-derived intoxicants like delta-8 THC. Those products grow out of the 2018 Farm Bill’s hemp definition and are tied to different federal rules.
    • Order the DEA to reschedule marijuana. The Court would be interpreting the Constitution and the CSA, not running agency science reviews.

    Any strong ruling might pressure Congress and agencies to act faster, but it would not replace those branches.

    To see how these branches interact in practice, the procedural history of Canna Provisions, Inc. v. Garland on CourtListener and other public sites shows how courts, agencies, and Congress each hold part of the puzzle.

    How Cannabis Businesses and Patients Can Prepare for Any Supreme Court Decision

    Federal law moves slowly, and court timelines can feel abstract. Cannabis operators and patients still have to make real decisions this week, this quarter, and this year.

    Here are ways to get ready without betting everything on any one outcome.

    Short term steps: stay compliant and watch the Court, not the rumors

    In the near term, the smartest move is to treat the law as it exists today.

    Helpful short-term practices include:

    • Stick to strong state compliance: Keep licenses current, follow testing and packaging rules, and document all processes. Good compliance records help with state regulators and make it easier to adapt if federal rules shift.
    • Work with qualified counsel: Regular check-ins with cannabis-savvy lawyers and accountants help catch issues early, especially around 280E, contracts, and ownership structures.
    • Track official updates: Follow the Supreme Court’s orders, not social media rumors. When the Court issues its December 15 order list, reputable news outlets and legal analysts will break it down quickly.
    • Avoid big moves based only on headlines: A grant of cert is not a win on the merits. A sharp reaction in stock prices or online forums does not replace a signed opinion.

    Ask internal teams: “What would we regret more, moving too fast or moving carefully after we see the actual decision?”

    Planning for a world with less federal risk around cannabis

    It still makes sense to think ahead about a friendlier federal environment, so long as planning does not become gambling.

    If the Court trims back federal power, operators might:

    • Revisit banking options and larger financial partners.
    • Update insurance coverage to match new risk levels.
    • Map possible expansions within a single state and, in time, across multiple legal states once Congress acts.
    • Polish brand and product strategies so they are ready for wider audiences when the rules allow.

    For patients and adult consumers, the most realistic changes would likely be:

    • More stable access to products and services.
    • Less fear about sudden federal crackdowns disrupting state programs.
    • Smoother experiences with payment, online ordering, and customer service.

    That is a picture of steady improvement, not an overnight flood of national cannabis products.

    Why the cannabis industry still needs Congress, even after this case

    Whatever the Supreme Court does, Congress will still control the big levers.

    Only Congress can:

    • Remove marijuana from Schedule I in the CSA.
    • Rewrite or repeal 280E for cannabis businesses.
    • Create national safety, labeling, and advertising standards.
    • Open clear paths for interstate commerce and imports or exports.

    Federal agencies, including the DEA, FDA, and banking regulators, then fill in the details through rules and guidance. Courts, including the Supreme Court, interpret those laws and rules.

    That means long-term change will still depend on policy work, trade groups, patient advocacy, and voter engagement. Court cases can speed or slow that process, but they rarely replace it.

    Conclusion

    Federal marijuana prohibition still shapes almost every part of the cannabis industry, from banking and taxes to hiring and patient access. Canna Provisions Inc. v. Garland asks the Supreme Court to rethink how far the CSA can reach into state-legal markets, and the December 15, 2025 cert decision will tell everyone whether the Court is ready to take that question.

    Three broad paths lie ahead: the Court could refuse the case and keep the status quo, hear it and uphold broad federal power, or hear it and limit federal reach over in-state, licensed cannabis. Each outcome carries different risks and opportunities for operators, workers, and patients, but none creates instant national legalization or erases the need for Congress to act.

    The smartest approach right now is calm preparation. Stay compliant, follow trusted legal and policy sources, and sketch out plans for several possible futures instead of betting on just one. MaryJanes Post will keep tracking this story so that cannabis professionals and patients have clear, practical updates as history unfolds.

  • Matthew Morgan, Cannaland and the Future


    If you’ve ever heard of cannabis companies like Reef Dispensaries, Ignite Cannabis Co., and Afternoon Delight — among many others — then you’ve likely heard the name Matthew Lee Morgan.

    Matthew Morgan is responsible for the success of several cannabis retail stores, two manufacturing plants, and two laboratories in multiple states. Today, he’s a lead player in Nevada’s recreational cannabis market, and we’re sure he won’t be stopping there.

    Essentially, he’s a cannasuccess.

    Recent News

    Recently Matthew has been brought on to consult Cannaland — Cannaversetech’s cannabis-themed community and meta marketplace. That’s right, Matthew Morgan’s next venture is about to launch in the metaverse, and it’s so much more than you can imagine it will be.

    This meta cannabis community will be a leading display of socially responsible cultivation, extraction, manufacturing, distribution, and even retail sales.

    It’s all about ensuring that the consumption of cannabis products of all kinds is enjoyed responsibly and appreciated thoroughly by the meta community’s residents.

    Blockchain For Cannabis

    The Cannaland Metaverse will reign in an innovative approach to community building. We’re talking revenue generation, manufacturing, product marketing and merchandising for all the cannabis brands looking to separate themselves from the rest of the already oversaturated physical marketplace.

    The goal?
    To open up an entirely new landscape where current cannabis brands can prepare for a globalized market. Laws pending, of course.

    Cannaversetech (Cannaverse Technologies) is easily considered the cannabis metaverse pioneer as the company is the first to even create a cannabis metaverse.

    With Matthew Morgan’s history of success in real estate and investments in the cannabis industry, there’s no doubt that Cannaland will reach its goals in supporting cannabis product marketing, manufacturing and merchandising — all within a uniquely innovative blockchain payment system.

    Supply Chain Talk

    Cannaland’s cannaverse isn’t just about selling cannabis to consumers. It’s about empowering cannabis cultivators, growers, efficient testing labs, and everyone else within the supply chain, from manufacturers to wholesalers to retailers.

    This would also include medical dispensaries and cannabis lounges, and bars. The innovation comes into play here as this new cannaverse offers the flexible ability to scale and monetize cannabis brands while directly addressing the existing (legal) gaps within the industry.

    Crypto Tokens

    This innovation would also include the CANNALAND token (CNLT). The CNLT will drive this cannaverse by enabling commerce within the community. The tokens themselves will provide consumers with both rewards as well as proof of ownership of certain goods, services, and properties providing more security than any land deed ever could.


    By putting Cannaland on the blockchain and with the help of Matthew Morgan’s expertise and major following, the global cannabis industry is as good as revolutionized. Once the cannabis metaverse is rolled out, every aspect of the industry right down to individual cannabis communities and consumers who take part will be connected indefinitely.


    Essentially, Cannaland will enable worldwide cannabis businesses to operate within just one domain without the limitations and localized legal constraints that exist within the cannabis industry today. It’s not just a brave new world for the cannabis industry — it’s the future.

  • G- Eazy and Flowershop* New Cannabis Feels

    G- Eazy and Flowershop* New Cannabis Feels

    FlowerShop*

    A brand created from a desire to help people connect with each other and their feelings, FlowerShop is a new upcoming cannabis business based on a health and wellness approach. 

    Flowershop* Products

    Isaac Muwaswes is the CEO of FlowerShop*, cannabis and lifestyle brand he co-founded with G-Eazy and Gabriel García. The brand is minority-owned with a focus on conceptual wellness and promoting sensory care techniques. Their approach differs from other cannabis brands; with the launch this week, the group’s focus was ensuring the message for FlowerShop as a universal language solely through their products. 

    Wellness

    Moving from the Midwest to the Bay Area, I learned different aspects of growing and indulging in cannabis. Besides being a drug to enhance your creativity, cannabis can also help with your health and wellness.

    FlowerShop is a brand created to help the world feel better through something they call “Sensory~Care: a mood-and-sensory-based approach to self-care, care for others, and caring for the planet.

    Wellness means something different for everyone; it’s less about dieting or restrictions for a workout regiment. The idea of conceptual wellness is finding your own definition of feeling well, and FlowerShop wants to be a part of that experience. The center of attention is to create products and experiences that cater to your senses or mood. Certain scents and aromas, music or food, can be connectivity. 

    Smoking weed with someone is like breaking bread; a positive experience and common ground with someone you just meet. It’s can also be integrated as a daily regime that gets you through your day.

    Co-founder Gabriel García unsurprisingly agrees, despite growing up in a context where cannabis was demonized. For him, FlowerShop* is about creating products that people can integrate into their routines to make them better.

    The small details are essential when making life changes. To see results in your health and wellness, you have to make an effort to change daily. 

    Pop Culture 

    The legalization of marijuana has begun to change the landscape of how others perceive the drug. A standard narrative that I relate with G-Eazy is sharing that I indulge in cannabis with my own parents. Though it wasn’t easy to admit, my reasoning other than creative is that the drug helps with my anxiety. 

    G-Eazy
    “G-Eazy at Ace of Spades Sacramento” by Kevin Cortopassi is licensed under CC BY-ND 2.0

    Being from Indiana, a conservative state, marijuana is demonized and frowned upon; people are still even being put in jail. With FlowerShop focusing on creating authentic relationships, they partnered with “The Last Prisoner Project,”.

    A group that helps raise awareness for all negativity that is affecting minority communities that have been convicted of nonviolent marijuana crimes that shouldn’t be in jail. A meaningful movement and selfless act that people can support. 

    While some other states are slowly coming to legalize, others embrace that cannabis is more than just a drug but a connector. Music and cannabis are simultaneously becoming one entity. While artists usually partake in the medicine for creative purposes, more are gaining a connection with it through their fan base.

    An example of this is part owner G-Eazy, who is one of the most prominent artists globally. With him being able to use his voice, FlowerShop should exceed expectations.

    Besides rhyming about products, G can also build with fans at dispensary locations. “The music will naturally have opportunities to talk about FlowerShop”; However, when I can go back to touring all over the world, I will leverage this and use my free time to go do events at dispensaries or to meet different partners. 

    That personal experience with his fan base is valuable and shows there’s a familiarity. A connection and likeness of a product which will grow the FlowerShop community.

    Retail Experience 

    There’s much positivity about FlowerShop, but the most crucial aspect is the retail component. The initiative for FlowerShop is to control the retail experience by creating a space where you can feel all five senses in one place. A full circle experience for the customer when entering the dispensary. What does it smell like, the design color scheme of the shop, and what music is playing? FlowerShop wants to trigger positive senses before you receive the product.

    The Company plans to brand the first applicant, located in Hollywood, FlowerShop*, a cannabis lifestyle and conceptual wellness brand by Feel Better in which G-Eazy is a partner and key member (CNW Group/Halo Collective Inc.)

    FlowerShop* and Halo Collective are working on three locations in Los Angeles, California, and the first dispensary will open by the end of 2021. In the meantime, the company will be doing pop-ups across local retailers they love and big chains, including Cookies, High Times, Barbary Coast, Harborside, and Sherbinskis — in addition to non-cannabis retailers like Bodega in LA and UNKWN in Miami.

    The Flower 

    The first three products that will be offered are our incense, candles, room spray, and essential oils. G-Eazy and one of his contacts in Japan developed a relationship to get a 100-plus-year-old incense manufacturer onboard in which they formulated their own fragrances. 

    Other products include Juice drop edibles, candles, ashtrays, and lifestyle fashion products. Items will be available online, and in the Bay Area, delivery will be an option.

  • Colorado Hemp Regulations Align With Federal Laws

    Colorado Hemp Regulations Align With Federal Laws

    Governor Jared Polis recently signed a bill that aligns Colorado hemp laws with federal regulations. The bill establishes authorized testing of all hemp lots and institutes penalties of around $2,000 per violation daily.

    The Farm Bill of 2018 allowed the U.S. Department of Agriculture to regulate hemp farming which focused on testing crops that contained more than 0.3% of tetrahydrocannabinol – an ingredient found in high concentrations in marijuana.

    According to Barbara McLachlan, one of the sponsors of the bill, “Colorado’s farmers are growing hemp on tens of thousands of acres across our state. Now that the federal government has finally recognized the agricultural importance of hemp, we’re bringing our state laws into alignment and streamlining regulations for our industrial producers. Colorado has never been afraid to lead the way and set an example for the rest of the country, and our hemp production industry is no different.”

    Read More from Us: Click Here maryjanespost